Presenter Dr. Alex Brunelli says neoadjuvant chemoimmunotherapy is a promising and well-tolerated treatment option in select patients with stage III NSCLC. Read more
Can radiotherapy replace surgery in stage III NSCLC in the era of immunotherapy? During ELCC 23, Dr. Sara Ramella turned to the data to answer that question. Read more
In a “tale of two trials,” Drs. Ogbeide and Osarogiagbon use insights from the ALCHEMIST trial population to try to understand outcomes disparities between North America and Japan. Read more
SABR patients were stable during the 12 months while surgical patients reported clinically significant deterioration at 6 weeks. Read more
Practical aspects of clinically managing operable SABR patients are important for the long-term care of this unique population. Read more
Surgery has long been the gold standard for diagnosis and management of early-stage operable lung cancer. For patients with inoperable disease or more extensive disease, however, alternative approaches are emerging. […] Read more
Transbronchial Microwave Ablation of Malignant Lung Nodules: Outcomes, Challenges, and Perspective
+more
With increasing availability of CT scans and strong evidence for the utility of low-dose CT screening in high-risk populations,1 an increasing number of small lung nodules are being incidentally discovered. […] Read more